welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Marina Biotech Announces $1.1 MM Convertible Preferred Stock Financing
Marina Biotech, Inc. ( OTCQB : MRNA ), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the company has entered into a definitive agreement with existing investors, led by Steven T. Newby and James H. Stebbins, for the issuance of convertible preferred stock at a conversion price equivalent to $0.40 per share of common stock resulting in gross proceeds to the company of $1.1 million. In addition, the Company will issue to the investors warrants to purchase up to 3,437,500 shares of common stock. The warrants will have an exercise price of $0.40 per share and are exercisable for a period of six years after the date of issuance. The offering is expected to close on or about August 7, 2015, subject to the satisfaction of customary closing conditions.
expertly curated content related to this topic
-
Brandie Leach, MS, CGCCurrently at Collaborative Group of the ...
-
PTSD common in patients with familial adenomatous polyposisPosttraumatic stress disorder is common ...
-
Matthew G. Mutch, MDMatthew G. Mutch, MD, is a Professor in ...
-
How do patients with rare Diseases Experience the Medical Encounter? Exploring Role Behavior and its Impact on Patie...OBJECTIVES: Empirical research shows th...
-
Robert Madoff, MDSpecialties/Interests: Colitis, Colon Ca...
-
East Belfast father and son using their love of cars to raise thousands for sick youngsterIain Craig and son Jacob are organising ...
-
#FAPAwarenessFAP hashtag for the community...